WINTON GROUP Ltd Sells 216,971 Shares of Roivant Sciences Ltd. $ROIV

WINTON GROUP Ltd reduced its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 39.9% in the 4th quarter, Holdings Channel reports. The fund owned 326,362 shares of the company’s stock after selling 216,971 shares during the quarter. WINTON GROUP Ltd’s holdings in Roivant Sciences were worth $7,082,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. TD Asset Management Inc raised its holdings in shares of Roivant Sciences by 94.7% during the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after acquiring an additional 153,800 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Roivant Sciences during the third quarter valued at approximately $877,000. HighVista Strategies LLC raised its holdings in shares of Roivant Sciences by 61.4% during the third quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock valued at $1,496,000 after acquiring an additional 37,590 shares in the last quarter. Neo Ivy Capital Management raised its holdings in shares of Roivant Sciences by 229.6% during the third quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock valued at $3,592,000 after acquiring an additional 165,362 shares in the last quarter. Finally, Capricorn Fund Managers Ltd raised its holdings in shares of Roivant Sciences by 124.4% during the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after acquiring an additional 247,000 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $48,827,417.01. This represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares in the company, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 945,173 shares of company stock valued at $27,654,456. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of a number of recent analyst reports. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Leerink Partners set a $42.00 target price on Roivant Sciences in a report on Thursday, May 21st. Finally, Guggenheim upped their target price on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Stock Down 3.2%

Shares of ROIV stock opened at $28.58 on Friday. The stock has a market cap of $20.56 billion, a price-to-earnings ratio of -47.63 and a beta of 1.13. The business’s fifty day moving average is $28.76 and its 200 day moving average is $25.67. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the firm earned ($0.29) earnings per share. Equities research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.